Dupilumab (Dupixent®) tends to be an effective therapy for uncontrolled severe chronic rhinosinusitis with nasal polyps: real data of a single-centered, retrospective single-arm longitudinal study from a university hospital in Germany

[1]  W. Fokkens,et al.  Real‐life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polyps , 2021, Allergy.

[2]  M. Ardeleanu,et al.  Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases , 2021, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[3]  C. Bachert,et al.  Dupilumab improves upper- and lower-airway disease control in chronic rhinosinusitis with nasal polyps and asthma. , 2021, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[4]  P. Kauppi,et al.  Factors affecting upper airway control of NSAID-exacerbated respiratory disease , 2020 .

[5]  S. Fujieda,et al.  The Effect of Dupilumab on Intractable Chronic Rhinosinusitis with Nasal Polyps in Japan , 2020, The Laryngoscope.

[6]  B. Söderquist,et al.  Long-Term Clinical Follow-Up of Patients With Chronic Rhinosinusitis , 2020, The Annals of otology, rhinology, and laryngology.

[7]  H. Sueki,et al.  Dupilumab treatment ameliorates clinical and hematological symptoms, including blood eosinophilia, in patients with atopic dermatitis , 2020, International journal of dermatology.

[8]  L. James,et al.  Dupilumab: Clinical Efficacy of Blocking IL-4/IL-13 Signalling in Chronic Rhinosinusitis with Nasal Polyps , 2020, Drug design, development and therapy.

[9]  Sheridan M. Hoy.  Dupilumab: A Review in Chronic Rhinosinusitis with Nasal Polyps , 2020, Drugs.

[10]  Chengshuo Wang,et al.  Distinct type 2-high inflammation associated molecular signatures of chronic rhinosinusitis with nasal polyps with comorbid asthma , 2020, Clinical and Translational Allergy.

[11]  W. Fokkens.  EPOS2020: a major step forward. , 2020, Rhinology.

[12]  D. Wang,et al.  European Position Paper on Rhinosinusitis and Nasal Polyps 2020. , 2020, Rhinology.

[13]  C. Bachert,et al.  Dupilumab improves health‐related quality of life in patients with chronic rhinosinusitis with nasal polyposis , 2019, Allergy.

[14]  A. Murphy,et al.  Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation , 2019, Allergy.

[15]  C. Bachert,et al.  Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials , 2019, The Lancet.

[16]  W. Liao,et al.  A review of dupilumab in the treatment of atopic diseases , 2019, Human vaccines & immunotherapeutics.

[17]  N. Bhattacharyya,et al.  Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps , 2019, The Laryngoscope.

[18]  C. Bachert,et al.  Dupilumab reduces local type 2 pro‐inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis , 2019, Allergy.

[19]  Andrew A. White,et al.  Diagnosis and management of NSAID‐Exacerbated Respiratory Disease (N‐ERD)—a EAACI position paper , 2018, Allergy.

[20]  I. Pavord,et al.  Dupilumab Efficacy and Safety in Moderate‐to‐Severe Uncontrolled Asthma , 2018, The New England journal of medicine.

[21]  A. Peters,et al.  Asthma onset pattern and patient outcomes in a chronic rhinosinusitis population , 2018, International forum of allergy & rhinology.

[22]  M. Okano,et al.  Pulmonary function in patients with eosinophilic chronic rhinosinusitis. , 2017, Auris, nasus, larynx.

[23]  H. Inohara,et al.  Lower Airway Inflammation in Eosinophilic Chronic Rhinosinusitis as Determined by Exhaled Nitric Oxide , 2017, International Archives of Allergy and Immunology.

[24]  A. Peters,et al.  Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease. , 2017, The journal of allergy and clinical immunology. In practice.

[25]  M. Shirley.  Dupilumab: First Global Approval , 2017, Drugs.

[26]  M. Citardi,et al.  Prevalence of confirmed asthma varies in chronic rhinosinusitis subtypes , 2016, International forum of allergy & rhinology.

[27]  Kristine A. Smith,et al.  Cost of adult chronic rhinosinusitis: A systematic review , 2015, The Laryngoscope.

[28]  L. Konge,et al.  A Comparative and Descriptive Study of Asthma in Chronic Rhinosinusitis with Nasal Polyps , 2014, American journal of rhinology & allergy.

[29]  D. Curran‐Everett,et al.  Unsupervised phenotyping of Severe Asthma Research Program participants using expanded lung data. , 2014, The Journal of allergy and clinical immunology.

[30]  C. Bachert,et al.  Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. , 2012, The Journal of allergy and clinical immunology.

[31]  J. Mullol,et al.  Persistent asthma has an accumulative impact on the loss of smell in patients with nasal polyposis. , 2011, Rhinology.

[32]  C. Bachert,et al.  Pathogenesis of chronic rhinosinusitis: inflammation. , 2011, The Journal of allergy and clinical immunology.

[33]  J Bousquet,et al.  Chronic rhinosinusitis in Europe – an underestimated disease. A GA2LEN study , 2011, Allergy.

[34]  L. Boulet,et al.  Comparative clinical and airway inflammatory features of asthmatics with or without polyps. , 2010, Rhinology.

[35]  D. Curran‐Everett,et al.  Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. , 2010, American journal of respiratory and critical care medicine.

[36]  K. Rabe,et al.  T cells and eosinophils in bronchial smooth muscle cell death in asthma , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[37]  R. Chandra,et al.  Relationships between Severity of Chronic Rhinosinusitis and Nasal Polyposis, Asthma, and Atopy , 2009, American journal of rhinology & allergy.

[38]  J. Domínguez-Ortega,et al.  Eosinophilic esophagitis due to profilin allergy. , 2009, Journal of investigational allergology & clinical immunology.

[39]  Jae Yong Lee,et al.  Comparison of the surgical outcome between primary and revision endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. , 2008, American journal of otolaryngology.

[40]  A. Murphy,et al.  Unique functions of the type II interleukin 4 receptor identified in mice lacking the interleukin 13 receptor α1 chain , 2008, Nature Immunology.

[41]  R. Levitt,et al.  Clinical Outcomes of Chronic Rhinosinusitis in Response to Medical Therapy: Results of a Prospective Study , 2007, American journal of rhinology.

[42]  C. Bachert,et al.  Differentiation of chronic sinus diseases by measurement of inflammatory mediators , 2006, Allergy.

[43]  N. Krug,et al.  Eosinophil cationic protein alters pulmonary surfactant structure and function in asthma. , 2004, The Journal of allergy and clinical immunology.

[44]  C. Beglinger,et al.  Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. , 2003, Gastroenterology.

[45]  A. Kampik,et al.  Toxic eosinophil granule protein deposition in corneal ulcerations and scars associated with atopic keratoconjunctivitis. , 2002, American journal of ophthalmology.

[46]  S. Guerra,et al.  Rhinitis as an independent risk factor for adult-onset asthma. , 2002, The Journal of allergy and clinical immunology.

[47]  Gerd Kobal,et al.  Screening of Olfactory Function with a Four-Minute Odor Identification Test: Reliability, Normative Data, and Investigations in Patients with Olfactory Loss , 2001, The Annals of otology, rhinology, and laryngology.

[48]  C. Bachert,et al.  Total and specific IgE in nasal polyps is related to local eosinophilic inflammation. , 2001, The Journal of allergy and clinical immunology.

[49]  T. Haahtela,et al.  Inflammatory cell and epithelial characteristics of perennial allergic and nonallergic rhinitis with a symptom history of 1 to 3 years' duration. , 2001, The Journal of allergy and clinical immunology.

[50]  D. Loegering,et al.  Toxicity of eosinophil cationic proteins for guinea pig tracheal epithelium in vitro. , 1989, The American review of respiratory disease.